Choroidal Neovascularization in Multifocal Choroiditis after Dabrafenib and Trametinib

Eur J Ophthalmol. 2017 Nov 8;27(6):e184-e186. doi: 10.5301/ejo.5001013.

Abstract

Purpose: To describe a case of bilateral choroidal neovascularization (CNV) in multifocal choroiditis (MFC) associated with dabrafenib and trametinib chemotherapy for metastatic melanoma.

Case: We present a case of a 57-year-old man with MFC who underwent combination therapy with dabrafenib plus trametinib for metastatic melanoma. The patient presented to our ophthalmology department complaining of bilateral vision loss of 2 days' duration. He underwent multimodal imaging showing a MFC reactivation complicated by bilateral CNV. The patient underwent 3 ranibizumab injections in the right eye and 7 ranibizumab injections in the left eye. Anatomical and functional improvement has been observed.

Conclusions: This report emphasizes the importance of strict ophthalmologic follow-up in patients with metastatic melanoma treated with dabrafenib plus trametinib since rare severe ocular toxicities can occur, especially in patients with a history of uveitis.

Keywords: Choroidal neovascularization; Dabrafenib and trametinib; Metastatic melanoma; Multifocal choroiditis.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Choroidal Neovascularization / drug therapy
  • Choroidal Neovascularization / etiology*
  • Choroiditis / complications*
  • Choroiditis / diagnosis
  • Fluorescein Angiography
  • Humans
  • Imidazoles / administration & dosage*
  • Male
  • Melanoma / drug therapy
  • Melanoma / secondary
  • Middle Aged
  • Multifocal Choroiditis
  • Multimodal Imaging
  • Oximes / administration & dosage*
  • Pyridones / administration & dosage*
  • Pyrimidinones / administration & dosage*
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / pathology
  • Tomography, Optical Coherence

Substances

  • Imidazoles
  • Oximes
  • Pyridones
  • Pyrimidinones
  • trametinib
  • dabrafenib